RXi partners with Calif. firm on cancer treatment research
Photo | Brad Kane
Geert Cauwenbergh, president and CEO, RXi Pharmaceuticals Corp., Marlborough.
Marlborough drugmaker RXi Pharmaceuticals has begun working with a California biotherapeutic firm to evaluate potential collaborations to create a new cancer treatment.
RXi’s research collaboration agreement with Iovance Biotherapeutics of San Carlos, Calif. Will evaluate potential synergies with RXi’s RNA therapeutic compounds and Iovance’s cell therapy based on tumor-infiltrating lymphocytes.
RXi President and CEO Geert Cauwenbergh called Iovance the leading company developing cancer treatment based on tumor-infiltrating lymphocyte technology.
The agreement will allow the companies to use their proprietary technologies together to improve the potency of tumor-infiltrating lymphocyte technology and potentially broaden the use of that technology in other types of tumors.
“We see this new research collaboration with the highly experienced Iovance team using TIL, as a major step to advance life-saving treatment approaches for solid tumors, a space where there is still a dire need for improved therapies for these patients,” Cauwenbergh said.
The research collaboration agreement comes in a year RXi has renewed its focus on developing cancer treatments using its self-delivering RNAi-based technology platform.
The company has formed four partnerships with European institutions and companies to expand its pipeline in the cancer-solving industry.
RXi has populated its leadership positions with immuno-oncology experts, including positions on its scientific advisory board, board of directors and the position of chief development officer.
WBJ Web Partners
Most Recent
Most Recent
0 Comments